These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11451210)

  • 21. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
    Yoshida K; Kohzuki M
    Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
    Chrysant SG; Marbury TC; Silfani TN
    Blood Press Monit; 2006 Jun; 11(3):135-41. PubMed ID: 16702822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
    Koike H; Sada T; Mizuno M
    J Hypertens Suppl; 2001 Jun; 19(1):S3-14. PubMed ID: 11451212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
    Brunner HR; Arakawa K
    Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.
    Smith DH
    Am J Cardiovasc Drugs; 2007; 7(5):347-56. PubMed ID: 17953473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.
    Sellin L; Stegbauer J; Laeis P; Rump LC
    J Hypertens; 2005 Nov; 23(11):2083-92. PubMed ID: 16208152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
    Ball KJ; Williams PA; Stumpe KO
    J Hypertens Suppl; 2001 Jun; 19(1):S49-56. PubMed ID: 11451215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.
    Püchler K; Laeis P; Stumpe KO
    J Hypertens Suppl; 2001 Jun; 19(1):S41-8. PubMed ID: 11451214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
    Wehling M
    Clin Ther; 2004; 26 Suppl A():A21-7. PubMed ID: 15291376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
    Chrysant SG; Melino M; Karki S; Lee J; Heyrman R
    Clin Ther; 2008 Apr; 30(4):587-604. PubMed ID: 18498909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
    Zannad F; Fay R
    Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olmesartan medoxomil: current status of its use in monotherapy.
    Brunner HR
    Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
    Smith RD; Yokoyama H; Averill DB; Cooke L; Brosnihan KB; Schiffrin EL; Ferrario CM
    Am J Cardiovasc Drugs; 2006; 6(5):335-42. PubMed ID: 17083268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
    Omboni S; Kario K; Bakris G; Parati G
    J Hypertens; 2018 Apr; 36(4):720-733. PubMed ID: 29045341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.